Every material Form 8-K Roivant Sciences has filed with the SEC since May 30, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Roivant and its subsidiary Priovant reported that brepocitinib 45 mg met the primary endpoint and all key secondary endpoints in the two identical Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis, with 371 patients enrolled. Priovant plans to file a supplemental New Drug Application for NIU in the first half of calendar 2027, which would be the next step toward a possible new treatment for the condition. The filing furnishes the press release under Regulation FD and contains no financial results.
Primary endpoint (time to treatment failure) met in CLARITY-1 (N=166) and CLARITY-2 (N=204); 371 patients enrolled in total
Median time to treatment failure was greater than 48 weeks in both studies, versus about 12 weeks on placebo (p<0.0001 in both)
Pooled, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48, versus 20% on placebo
Priovant intends to file the sNDA in the first half of calendar 2027; Roivant investor call set for 8:00 a.m. ET on October 21, 2026
Roivant reported a net loss of $290.6 million for the quarter ended June 30, 2026, up from $273.9 million a year earlier, on revenue of $1.4 million versus $2.2 million. Net loss per share narrowed to $0.26 from $0.33, and the net loss attributable to Roivant Sciences Ltd. was $189.8 million versus $223.4 million, while R&D and G&A expenses both rose.
Net loss per common share was $0.26 versus $0.33 a year earlier; non-GAAP net loss was $243.7 million versus $170.1 million.
R&D expenses rose $49.1 million to $202.0 million; G&A expenses rose $31.5 million to $165.5 million.
Roivant repurchased 7.3 million common shares for about $208.7 million in the quarter.
Cash, cash equivalents, restricted cash and marketable securities were $3.9 billion at June 30, 2026, excluding the $950 million Moderna payment received in July 2026.
Roivant reported fourth-quarter net income attributable to the company of $303 million, compared with a loss of $206 million a year earlier, mainly due to a $770.2 million gain on the Moderna litigation settlement. Q4 revenue fell to $2.5 million from $7.6 million, and the full-year net loss attributable to the company widened to $299.8 million from $172.0 million, so the one-time gain does not reflect a steady operating improvement.
Q4 ended March 31, 2026: net income attributable to Roivant $303.0 million, or $0.28 diluted per share, versus a loss of $206.5 million ($0.29 per share) a year earlier
Gain on litigation settlement of $770.2 million; Q4 revenue $2.5 million versus $7.6 million
Full year: loss from continuing operations $397.9 million versus $729.8 million; net loss attributable to Roivant $299.8 million versus $172.0 million
Cash, cash equivalents and marketable securities of $4.3 billion as of March 31, 2026; Moderna to pay $950 million in July 2026 with an additional $1.3 billion contingent on an appeal
Roivant said its Immunovant unit's two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint, and it started a new Phase 2b/3 trial of brepocitinib in lichen planopilaris at Priovant. The filing also gave preliminary cash and marketable securities of about $4.3 billion as of March 31, 2026, and buybacks of about $109.7 million in the quarter, while the fiscal year audit is still ongoing.
Immunovant's two Phase 3 batoclimab studies in thyroid eye disease each failed to meet the primary endpoint of at least 2mm proptosis responder rate at Week 24; no new safety signals were identified.
Priovant began a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first subjects enrolled in March 2026.
Preliminary cash, cash equivalents and marketable securities were about $4.3 billion as of March 31, 2026.
Roivant repurchased 3,956,362 common shares for about $109.7 million (excluding fees and commission) in the three months ended March 31, 2026.
Genevant and Arbutus, both tied to Roivant, agreed to settle their patent infringement litigation against Moderna over LNP technology in its COVID-19 vaccines. Moderna will pay $950 million by July 8, 2026, plus a contingent $1.3 billion tied to a Federal Circuit appeal on 28 U.S.C. §1498. Roivant's board also raised its share repurchase authorization to $1.0 billion, including the previously approved $500 million.
Moderna to pay a noncontingent $950 million lump sum on or before July 8, 2026
Additional $1.3 billion contingent payment depends on the Federal Circuit's §1498 ruling; a partial outcome yields a prorated amount
Board increased the share repurchase program to up to $1.0 billion, funded with cash on hand, with no expiration date
Roivant reported a net loss attributable to Roivant Sciences Ltd. of $265.9 million, or $0.38 per share, for the quarter ended December 31, 2025, compared with net income of $169.4 million a year earlier. The prior-year result included a $327.0 million gain from discontinued operations tied to the Dermavant sale, and the loss from continuing operations rose to $313.7 million from $208.9 million, so shareholders face a larger operating loss even as the company reported positive Phase 2 brepocitinib data in cutaneous sarcoidosis.
Revenue was $2.0 million for the quarter, down from $9.0 million a year earlier
Loss from continuing operations was $0.38 per share, compared with $0.22 per share a year earlier
R&D expenses rose $23.8 million to $165.4 million; G&A rose $33.5 million to $175.1 million, including a $17.1 million headquarters impairment
Consolidated cash, cash equivalents, restricted cash and marketable securities totaled $4.5 billion as of December 31, 2025
Roivant reported results for the quarter ended September 30, 2025. Net loss attributable to Roivant shareholders narrowed to $113.5 million from $230.2 million a year earlier, while revenue fell to $1.6 million from $4.5 million. R&D spending rose, and the company reported $4.4 billion in cash, cash equivalents, restricted cash and marketable securities.
Net loss attributable to Roivant was $113.5 million, or $0.17 per share, versus $230.2 million, or $0.31 per share, a year earlier
Revenue was $1.6 million versus $4.5 million in the prior-year quarter
R&D expenses rose to $164.6 million from $143.1 million; G&A expenses fell to $143.1 million from $202.9 million
Cash and marketable securities totaled $4.4 billion as of September 30, 2025; Investor Day is set for December 11, 2025
Roivant reported a loss from continuing operations of $273.9 million for the quarter ended June 30, 2025, compared with income of $31.6 million a year earlier, or $0.33 loss per share versus $0.01 income per share. Revenue fell to $2.2 million from $8.0 million, while research and development and general and administrative expenses rose, and share-based compensation increased sharply.
Revenue was $2.2 million versus $8.0 million in the prior-year quarter
Research and development expenses rose $32.4 million to $152.9 million; general and administrative expenses rose $34.1 million to $134.0 million
Share-based compensation in general and administrative expenses was $71.1 million versus $36.8 million
Cash, cash equivalents, restricted cash and marketable securities were $4.5 billion at June 30, 2025; a new $500 million buyback was approved in June 2025
Roivant reported a loss from continuing operations of $252.4 million for the three months ended March 31, 2025, compared with a $95.0 million loss a year earlier, on revenue of $7.6 million versus $9.0 million. For the fiscal year, it reported a $729.8 million loss from continuing operations, compared with income of approximately $4.5 billion in the prior year, which included a gain on the Telavant net assets sale. The company repurchased $1.3 billion of shares, cutting outstanding shares by 14%, and ended the period with $4.9 billion in cash, cash equivalents, restricted cash and marketable securities.
Q4 revenue was $7.6 million versus $9.0 million a year earlier; R&D expenses rose to $145.2 million from $107.6 million
Fiscal year loss from continuing operations of $729.8 million, compared with income of approximately $4.5 billion in fiscal 2024
Share repurchases of $1.3 billion as of March 31, 2025, reducing outstanding shares by 14% from March 31, 2024
Cash, cash equivalents, restricted cash and marketable securities of $4.9 billion at March 31, 2025
Roivant Sciences disclosed that its subsidiary, Roivant Sciences, Inc., signed a consulting agreement on March 16, 2025 with Rakhi Kumar, its former Chief Accounting Officer, who stepped down on February 20, 2025. Under the 18-month agreement, Ms. Kumar will provide advisory and transition services and may keep vesting in her outstanding equity awards, with any remaining unvested awards fully vesting at the end of the term if she meets her obligations. The filing is administrative and discloses no financial figures.
Consulting agreement dated March 16, 2025 with former Chief Accounting Officer Rakhi Kumar
Ms. Kumar stepped down effective February 20, 2025, as previously disclosed in a February 21, 2025 Form 8-K
Agreement runs 18 months and lets her continue vesting in outstanding equity incentive awards
Unvested awards fully vest at the end of the term if she complies with her separation obligations and the agreement is not terminated early
Roivant Sciences said Rakhi Kumar stepped down as Principal Accounting Officer and Chief Accounting Officer of its subsidiary Roivant Sciences, Inc., effective February 20, 2025. Jennifer Humes, a former JPMorgan Chase Managing Director, was appointed to both roles from the same date. The change affects the company's principal accounting officer, a role responsible for financial reporting, but the filing reports no financial results.
Rakhi Kumar stepped down effective February 20, 2025, and the company thanked her for her service.
Jennifer Humes was appointed Principal Accounting Officer and Chief Accounting Officer of RSI effective February 20, 2025.
Humes's offer letter includes a $380,000 base salary, a $190,000 target annual cash bonus, and a $261,500 sign-on bonus.
Equity grants have estimated values of approximately $1.2 million in RSUs and $800,000 in stock options, vesting over multiple years.
Roivant reported results for the quarter ended December 31, 2024. Revenue fell to $9.0 million from $15.6 million a year earlier, and the loss from continuing operations was $208.9 million, or $0.22 per share, compared with income of about $5.1 billion a year earlier, which included a one-time Telavant gain. Net income attributable to Roivant was $169.4 million, driven by a $327.0 million gain from discontinued operations tied to the sale of Dermavant to Organon.
Revenue, net was $9.0 million for the three months ended December 31, 2024, versus $15.6 million a year earlier.
R&D expenses rose $33.4 million to $141.6 million; G&A expenses rose $13.4 million to $141.5 million.
Income from discontinued operations was $327.0 million, reflecting the October 2024 sale of Dermavant to Organon.
Consolidated cash, cash equivalents, restricted cash and marketable securities were about $5.2 billion at December 31, 2024.
Roivant reported results for the quarter ended September 30, 2024, with a net loss attributable to the company of $230.2 million, or $0.31 per share, compared with $304.3 million, or $0.40 per share, a year earlier. Net revenue rose to $4.5 million from $3.6 million, but general and administrative expenses rose to $202.9 million, including $79.1 million of one-time cash retention awards, and the non-GAAP loss from continuing operations widened to $218.7 million from $154.8 million.
Net loss attributable to Roivant was $230.2 million ($0.31 per share) vs. $304.3 million ($0.40 per share) a year earlier.
Revenue, net was $4.5 million vs. $3.6 million; R&D expenses were $143.1 million vs. $114.8 million.
G&A expenses were $202.9 million vs. $88.6 million, including $79.1 million of one-time cash retention awards approved in July 2024.
Cash, cash equivalents and marketable securities were approximately $5.4 billion at September 30, 2024, after $106 million of share repurchases in the quarter.
Roivant's subsidiary Dermavant agreed on September 17, 2024 to be acquired by Organon for up to about $1.2 billion, including a $175 million payment at closing, a $75 million milestone on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in sales-based milestones, plus tiered royalties. Roivant owns about 87% of Dermavant's shares, so the deal would deliver most of the proceeds to Roivant, though the amount depends on future milestones and the closing is subject to conditions.
Organon agreed to acquire Dermavant for up to about $1.2 billion in aggregate cash consideration, including a $175 million payment at closing
Additional $75 million payable on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in tiered net sales milestones
Roivant owns approximately 87% of Dermavant's common and preference shares; shareholder written consent of at least 75% of voting rights was obtained
Expected to close in the fourth quarter of 2024; either party may terminate if not closed by March 17, 2025
Roivant reported results for the fiscal quarter ended June 30, 2024, with revenue of $55.1 million, up from $21.6 million a year earlier, and net income of $57.5 million compared with a net loss of $327.8 million. The profit includes a $110.4 million gain on the sale of Telavant net assets, and the company's non-GAAP net loss was $131.2 million, narrower than $211.5 million a year earlier.
Revenue, net was $55.1 million versus $21.6 million a year earlier; product revenue, net was $18.4 million
Net income was $57.5 million, or $0.13 basic and $0.12 diluted per share, versus a net loss of $0.38 per share a year earlier
Gain on sale of Telavant net assets of $110.4 million; non-GAAP net loss was $131.2 million versus $211.5 million
Cash, cash equivalents and restricted cash were approximately $5.7 billion at June 30, 2024, after a $648 million share repurchase announced in April 2024
On May 24, 2024, Roivant subsidiary Dermavant Sciences Ltd. entered into agreements to renegotiate its debt, which the filing says would reduce potential cash payments by over $300 million in aggregate. Roivant will contribute $195 million in preferred equity to Dermavant, and the royalty purchasers and NovaQuest receive about 13.2% of Dermavant's shares, leaving Roivant with about 87% of common and preferred shares after closing. For shareholders, the deal lowers future cash obligations but dilutes Roivant's stake in Dermavant and raises the interest rate on one credit agreement.
Debt Renegotiation expected to reduce potential cash payments by over $300 million in aggregate, with about $225 million achieved over the next three fiscal years.
Roivant to contribute $195 million to Dermavant for convertible preferred shares with a liquidation preference of 1.5 times invested capital.
Credit Agreement maturity extended from May 2026 to May 2028, with the interest rate rising from 10% to 12.25% per annum.
NovaQuest eliminates fixed quarterly payments totaling $176.3 million and milestone payments of up to $141.0 million; remaining payments of $122.5 million run through March 31, 2029.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Roivant Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →